A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.

Citation

• Lee, D. H., Roohullah, A., Cho, B. C., Lemech, C. R., de Souza, P. L., Millward, M., . . . Han, J. -Y. (2022). A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.. Journal of Clinical Oncology, 40(16_suppl), 3105. doi:10.1200/jco.2022.40.16_suppl.3105

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.3105

Web Of Science Accession Number

Start Page

• 3105

End Page

• 3105

Volume

• 40

Issue

• 16_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2022

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Lee, D. H., Roohullah, A., Cho, B. C., Lemech, C. R., de Souza, P. L., Millward, M., . . . Han, J. -Y. (2022). A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.. Journal of Clinical Oncology, 40(16_suppl), 3105. doi:10.1200/jco.2022.40.16_suppl.3105

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.3105

Web Of Science Accession Number

Start Page

• 3105

End Page

• 3105

Volume

• 40

Issue

• 16_suppl

Place Of Publication